Opinion|Videos|September 3, 2024
Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial
Medical experts offer insights on the COMMANDS trial findings.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the expanded indication of luspatercept in lower-risk myelodysplastic syndromes (based on the COMMANDS trial findings) and its implications for clinical practice.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
5 FAQs: Ebola Outbreaks and the Challenge of Public Trust
2
Targeting Oxidative Stress Could Fill a Gap in the Vitiligo Treatment Toolbox
3
How Hospital Specialty Pharmacies Are Closing the Pharmacy Desert Gap
4
Patients on GLP-1s Increasingly Carry Diagnoses for New Indications
5